Enliven Therapeutics (ELVN) Competitors $20.82 -0.47 (-2.21%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$20.76 -0.05 (-0.26%) As of 10/10/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELVN vs. ACLX, KYMR, PTGX, CRNX, SRRK, MENS, AAPG, AKRO, ZLAB, and MIRMShould you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include Arcellx (ACLX), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), Scholar Rock (SRRK), Jyong Biotech (MENS), Ascentage Pharma Group International (AAPG), Akero Therapeutics (AKRO), Zai Lab (ZLAB), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. Enliven Therapeutics vs. Its Competitors Arcellx Kymera Therapeutics Protagonist Therapeutics Crinetics Pharmaceuticals Scholar Rock Jyong Biotech Ascentage Pharma Group International Akero Therapeutics Zai Lab Mirum Pharmaceuticals Arcellx (NASDAQ:ACLX) and Enliven Therapeutics (NASDAQ:ELVN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends. Do analysts rate ACLX or ELVN? Arcellx currently has a consensus target price of $112.69, indicating a potential upside of 29.83%. Enliven Therapeutics has a consensus target price of $41.20, indicating a potential upside of 97.89%. Given Enliven Therapeutics' higher probable upside, analysts clearly believe Enliven Therapeutics is more favorable than Arcellx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcellx 1 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.87Enliven Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do institutionals & insiders believe in ACLX or ELVN? 96.0% of Arcellx shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 8.4% of Arcellx shares are owned by insiders. Comparatively, 25.9% of Enliven Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, ACLX or ELVN? Arcellx has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Is ACLX or ELVN more profitable? Enliven Therapeutics has a net margin of 0.00% compared to Arcellx's net margin of -329.93%. Enliven Therapeutics' return on equity of -29.15% beat Arcellx's return on equity.Company Net Margins Return on Equity Return on Assets Arcellx-329.93% -43.04% -27.41% Enliven Therapeutics N/A -29.15%-27.88% Does the media prefer ACLX or ELVN? In the previous week, Arcellx had 1 more articles in the media than Enliven Therapeutics. MarketBeat recorded 7 mentions for Arcellx and 6 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.39 beat Arcellx's score of 0.33 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcellx 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enliven Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings & valuation, ACLX or ELVN? Enliven Therapeutics has lower revenue, but higher earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcellx$107.94M44.60-$107.35M-$3.42-25.38Enliven TherapeuticsN/AN/A-$89.02M-$2.00-10.41 SummaryEnliven Therapeutics beats Arcellx on 9 of the 16 factors compared between the two stocks. Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELVN vs. The Competition Export to ExcelMetricEnliven TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.26B$2.65B$6.11B$10.63BDividend YieldN/A56.72%5.66%4.71%P/E Ratio-10.4122.9185.2726.57Price / SalesN/A745.20612.78132.63Price / CashN/A179.8938.5062.09Price / Book3.285.3712.726.53Net Income-$89.02M$32.78M$3.30B$275.96M7 Day Performance6.17%2.34%0.94%-0.73%1 Month Performance4.52%8.04%6.34%3.71%1 Year Performance-25.40%-1.76%80.41%37.30% Enliven Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELVNEnliven Therapeutics2.4989 of 5 stars$20.82-2.2%$41.20+97.9%-22.8%$1.26BN/A-10.4150Analyst ForecastInsider TradeACLXArcellx2.1666 of 5 stars$83.85-0.6%$114.31+36.3%+4.7%$4.65B$107.94M-24.5280News CoverageAnalyst ForecastKYMRKymera Therapeutics1.7625 of 5 stars$56.58-1.7%$61.26+8.3%+32.3%$4.07B$44.71M-16.40170Analyst ForecastPTGXProtagonist Therapeutics1.6659 of 5 stars$63.25-1.4%$68.36+8.1%+99.6%$3.93B$209.18M90.36120Trending NewsAnalyst ForecastCRNXCrinetics Pharmaceuticals3.779 of 5 stars$41.57-0.3%$74.45+79.1%-13.2%$3.91B$1.39M-10.11210Analyst ForecastSRRKScholar Rock4.5158 of 5 stars$39.82+0.0%$46.40+16.5%+51.0%$3.83BN/A-13.69140Analyst ForecastInsider TradeMENSJyong BiotechN/A$50.22-3.4%N/AN/A$3.82BN/A0.0031Analyst ForecastAAPGAscentage Pharma Group InternationalN/A$39.86+1.2%N/AN/A$3.71B$134.35M0.00600News CoverageAKROAkero Therapeutics3.6947 of 5 stars$46.32+0.6%$81.14+75.2%+85.3%$3.70BN/A-23.1630Trending NewsAnalyst ForecastInsider TradeZLABZai Lab2.7992 of 5 stars$33.09-0.7%$56.35+70.3%+19.4%$3.70B$398.99M-16.221,869News CoveragePositive NewsAnalyst ForecastMIRMMirum Pharmaceuticals2.9902 of 5 stars$73.09+0.8%$76.50+4.7%+89.0%$3.67B$336.89M-60.41140News CoverageAnalyst Forecast Related Companies and Tools Related Companies Arcellx Competitors Kymera Therapeutics Competitors Protagonist Therapeutics Competitors Crinetics Pharmaceuticals Competitors Scholar Rock Competitors Jyong Biotech Competitors Ascentage Pharma Group International Competitors Akero Therapeutics Competitors Zai Lab Competitors Mirum Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELVN) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
